A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced on Monday that its experimental drug, when combined with Novo ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

The probiotic is unique in its method, using genetically engineered Lactobacillus casei to generate an immune response against myostatin, facilitating muscle preservation during weight loss ...

Regeneron has said it will abide by 23andMe’s privacy ... (Church and Smith, 5/19) Becker's Hospital Review: Mayo Clinic Discovery May Extend Donor Heart Preservation: 4 Study Notes Researchers from ...

low dose ASC47 in combination with semaglutide demonstrated a 56.7% greater reduction in body weight with muscle preservation compared to semaglutide monotherapy. Topline data from the ASC47-103 study ...

It comes two months after 23andMe filed for Chapter 11 bankruptcy. Under the deal, Westchester County, New York-based Regeneron will take over 23andMe's personal genome service, total health, and ...